Optimal use of SGLT2 inhibitors in diabetic kidney transplant recipients
Sodium-glucose cotransporter 2 inhibitor (SGLT2i), a glucosuric agent initially approved for use as an antidiabetic agent, was unexpectedly found to confer cardio-and reno-protective effects in individuals with or without type 2 diabetes mellitus. Despite mounting evidence suggesting that SGLT2i pro...
Saved in:
| Published in: | Frontiers in Nephrology (Online) Vol. 2; p. 1014241 |
|---|---|
| Main Authors: | , |
| Format: | Journal Article |
| Language: | English |
| Published: |
Switzerland
Frontiers Media S.A
10-11-2022
|
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Sodium-glucose cotransporter 2 inhibitor (SGLT2i), a glucosuric agent initially approved for use as an antidiabetic agent, was unexpectedly found to confer cardio-and reno-protective effects in individuals with or without type 2 diabetes mellitus. Despite mounting evidence suggesting that SGLT2i provides cardio- and reno-protective benefits in both diabetic and non-diabetic and in chronic kidney disease (CKD) patients in the general population, reservations for its use in the transplant setting persist due to concerns for increased risk of genital mycotic and urinary tract infections. A comprehensive review of the literature on the efficacy and safety of SGLT2i use in diabetic kidney transplant recipients is herein presented followed by authors' opinion on its optimal use in this patient population. |
|---|---|
| AbstractList | Sodium-glucose cotransporter 2 inhibitor (SGLT2i), a glucosuric agent initially approved for use as an antidiabetic agent, was unexpectedly found to confer cardio-and reno-protective effects in individuals with or without type 2 diabetes mellitus. Despite mounting evidence suggesting that SGLT2i provides cardio- and reno-protective benefits in both diabetic and non-diabetic and in chronic kidney disease (CKD) patients in the general population, reservations for its use in the transplant setting persist due to concerns for increased risk of genital mycotic and urinary tract infections. A comprehensive review of the literature on the efficacy and safety of SGLT2i use in diabetic kidney transplant recipients is herein presented followed by authors’ opinion on its optimal use in this patient population. Sodium-glucose cotransporter 2 inhibitor (SGLT2i), a glucosuric agent initially approved for use as an antidiabetic agent, was unexpectedly found to confer cardio-and reno-protective effects in individuals with or without type 2 diabetes mellitus. Despite mounting evidence suggesting that SGLT2i provides cardio- and reno-protective benefits in both diabetic and non-diabetic and in chronic kidney disease (CKD) patients in the general population, reservations for its use in the transplant setting persist due to concerns for increased risk of genital mycotic and urinary tract infections. A comprehensive review of the literature on the efficacy and safety of SGLT2i use in diabetic kidney transplant recipients is herein presented followed by authors' opinion on its optimal use in this patient population.Sodium-glucose cotransporter 2 inhibitor (SGLT2i), a glucosuric agent initially approved for use as an antidiabetic agent, was unexpectedly found to confer cardio-and reno-protective effects in individuals with or without type 2 diabetes mellitus. Despite mounting evidence suggesting that SGLT2i provides cardio- and reno-protective benefits in both diabetic and non-diabetic and in chronic kidney disease (CKD) patients in the general population, reservations for its use in the transplant setting persist due to concerns for increased risk of genital mycotic and urinary tract infections. A comprehensive review of the literature on the efficacy and safety of SGLT2i use in diabetic kidney transplant recipients is herein presented followed by authors' opinion on its optimal use in this patient population. |
| Author | Pham, Phuong-Chi T Pham, Phuong-Thu T |
| AuthorAffiliation | 1 Nephrology Division, Kidney Transplant Program David Geffen School of Medicine at University of California at Los Angeles (UCLA) , Los Angeles, CA , United States 2 Division of Nephrology and Hypertension Olive-View University of California at Los Angeles (UCLA) Medical Center , Sylmar, CA , United States 3 David Geffen School of Medicine at University of California at Los Angeles (UCLA) , Los Angeles, CA , United States |
| AuthorAffiliation_xml | – name: 2 Division of Nephrology and Hypertension Olive-View University of California at Los Angeles (UCLA) Medical Center , Sylmar, CA , United States – name: 3 David Geffen School of Medicine at University of California at Los Angeles (UCLA) , Los Angeles, CA , United States – name: 1 Nephrology Division, Kidney Transplant Program David Geffen School of Medicine at University of California at Los Angeles (UCLA) , Los Angeles, CA , United States |
| Author_xml | – sequence: 1 givenname: Phuong-Thu T surname: Pham fullname: Pham, Phuong-Thu T organization: Nephrology Division, Kidney Transplant Program David Geffen School of Medicine at University of California at Los Angeles (UCLA), Los Angeles, CA, United States – sequence: 2 givenname: Phuong-Chi T surname: Pham fullname: Pham, Phuong-Chi T organization: David Geffen School of Medicine at University of California at Los Angeles (UCLA), Los Angeles, CA, United States |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/37674999$$D View this record in MEDLINE/PubMed |
| BookMark | eNpVUctOwzAQtBCIFugPcEA5cknxK459QqiCglSJA-VsucmaGlIn2ClS_x5DS1VOO9LuzO7snKFj33pA6JLgMWNS3VgP3XJMMaVjggmnnByhIZWE5VhQcXyAB2gU4zvGmMqS41KdogErRcmVUkP0-Nz1bmWabB0ha232Mp3Naeb80i1c34aYYFY7s4DeVdmHqz1ssj4YH7vG-D4LULnOge_jBTqxpokw2tVz9PpwP5885rPn6dPkbpZXlEuS17WFwhaSGVZYztINVlgLGGhRM8IwCGOlwJTXXFYFV4YLLBghySdXlAI7R7db3W69WEFdpd3BNLoLyUXY6NY4_b_j3VK_tV-aYF4qUYikcL1TCO3nGmKvVy5W0CRD0K6jplJQopTERRql29EqtDEGsPs9BOufGPRvDPonBr2LIZGuDi_cU_6ezr4BN26F-A |
| CitedBy_id | crossref_primary_10_3389_fneph_2024_1332397 crossref_primary_10_3389_fphar_2024_1356991 |
| Cites_doi | 10.1161/CIRCULATIONAHA.120.051685 10.1053/j.ajkd.2020.05.014 10.1097/TP.0000000000004228 10.2337/dc17-0237 10.1002/edm2.185 10.1053/j.ajkd.2016.08.018 10.1016/j.transproceed.2019.11.007 10.1016/j.transproceed.2019.05.023 10.1016/S2213-8587(19)30256-6 10.1097/TP.0000000000004227 10.1186/s12933-021-01301-x 10.4103/ijn.IJN_2_18 10.1016/j.jacc.2019.11.031 10.1111/ajt.15223 10.1016/S0140-6736(18)32590-X 10.2337/dc19-0093 10.1056/NEJMoa2107038 10.1053/j.ajkd.2020.06.018 10.1111/ajt.14316 10.3390/medsci8040047 10.1007/s00125-019-4859-4 10.1159/000507272 10.1111/ctr.14718 10.1161/CIRCULATIONAHA.116.021887 10.1159/000501854 10.1093/ndt/gfz103.SP770 |
| ContentType | Journal Article |
| Copyright | Copyright © 2022 Pham and Pham. Copyright © 2022 Pham and Pham 2022 Pham and Pham |
| Copyright_xml | – notice: Copyright © 2022 Pham and Pham. – notice: Copyright © 2022 Pham and Pham 2022 Pham and Pham |
| DBID | NPM AAYXX CITATION 7X8 5PM |
| DOI | 10.3389/fneph.2022.1014241 |
| DatabaseName | PubMed CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | PubMed CrossRef MEDLINE - Academic |
| DatabaseTitleList | CrossRef MEDLINE - Academic PubMed |
| DeliveryMethod | fulltext_linktorsrc |
| EISSN | 2813-0626 |
| ExternalDocumentID | 10_3389_fneph_2022_1014241 37674999 |
| Genre | Journal Article Review |
| GroupedDBID | 53G 9T4 ALMA_UNASSIGNED_HOLDINGS GROUPED_DOAJ M~E NPM PGMZT RPM AAYXX CITATION 7X8 5PM AFPKN |
| ID | FETCH-LOGICAL-c2481-ddfe5f583a35f43999f6ffe0e25d3130e6af86024d48c549a46063110224922e3 |
| IEDL.DBID | RPM |
| ISSN | 2813-0626 |
| IngestDate | Tue Sep 17 21:29:40 EDT 2024 Sat Oct 26 02:50:51 EDT 2024 Thu Nov 21 22:53:21 EST 2024 Sat Nov 02 12:29:12 EDT 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | diabetic kidney disease kidney transplantation PTDM post-transplantation diabetes mellitus sodium-glucose cotransporter 2 inhibitor diabetic kidney transplant recipients SGLT2 inhibitor |
| Language | English |
| License | Copyright © 2022 Pham and Pham. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c2481-ddfe5f583a35f43999f6ffe0e25d3130e6af86024d48c549a46063110224922e3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 Reviewed by: Ayman Al Jurdi, Massachusetts General Hospital, Harvard Medical School, United States; Chi Yuen Simon Cheung, Queen Elizabeth Hospital (QEH), Hong Kong SAR, China Edited by: Masoud Sadeghi, Kermanshah University of Medical Sciences, Iran This article was submitted to Kidney Transplantation, a section of the journal Frontiers in Nephrology |
| OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10479656/ |
| PMID | 37674999 |
| PQID | 2862199805 |
| PQPubID | 23479 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_10479656 proquest_miscellaneous_2862199805 crossref_primary_10_3389_fneph_2022_1014241 pubmed_primary_37674999 |
| PublicationCentury | 2000 |
| PublicationDate | 20221110 |
| PublicationDateYYYYMMDD | 2022-11-10 |
| PublicationDate_xml | – month: 11 year: 2022 text: 20221110 day: 10 |
| PublicationDecade | 2020 |
| PublicationPlace | Switzerland |
| PublicationPlace_xml | – name: Switzerland |
| PublicationTitle | Frontiers in Nephrology (Online) |
| PublicationTitleAlternate | Front Nephrol |
| PublicationYear | 2022 |
| Publisher | Frontiers Media S.A |
| Publisher_xml | – name: Frontiers Media S.A |
| References | Francis (B20) 2022; 106 Rajasekeran (B9) 2017; 40 Zelniker (B2) 2019; 393 Neuen (B5) 2021; 77 Yagan (B27) 2022; 22 Anker (B4) 2021; 385 Attallah (B12) 2019; 51 Chewcharat (B16) 2020; 8 Sridhar (B21) 2020; 76 Jin (B23) 2017; 17 Zelniker (B3) 2020; 75 Shah (B11) 2019; 29 Zannad (B7) 2021; 143 Schwaiger (B10) 2019; 19 Halden (B8) 2019; 42 Kong (B14) 2019; 34 Song (B26) 2022; 22 Hiremath (B22) 2017; 69 Potier (B24) 2021; 20 Mahling (B13) 2019; 44 Lemke (B18) 2022; 36 Neuen (B6) 2019; 7 Heerspink (B1) 2016; 134 Mahmoud (B25) 2022; 22 Alkindi (B15) 2020; 52 Song (B17) 2020; 4 Heerspink (B29) 2019; 62 Marathias (B28) 2020; 51 Lim (B19) 2022; 106 |
| References_xml | – volume: 143 year: 2021 ident: B7 article-title: Cardiac and kidney benefits of empagliflozin in heart failure across the spectrum of kidney function: Insights from EMPEROR-reduced publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.120.051685 contributor: fullname: Zannad – volume: 22 year: 2022 ident: B25 article-title: Outcomes of sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists in diabetic kidney transplant recipients publication-title: Am J Transplant contributor: fullname: Mahmoud – volume: 76 year: 2020 ident: B21 article-title: We can finally stop worrying about SGLT2 inhibitors and acute kidney injury publication-title: Am J Kidney Dis doi: 10.1053/j.ajkd.2020.05.014 contributor: fullname: Sridhar – volume: 106 year: 2022 ident: B19 article-title: The efficacy and safety of SGLT2 inhibitor in diabetic kidney transplant recipients publication-title: Transplantation doi: 10.1097/TP.0000000000004228 contributor: fullname: Lim – volume: 40 year: 2017 ident: B9 article-title: Use of canagliflozin in kidney transplant recipients for the treatment of type 2 diabetes: A case series publication-title: Diabetes Care doi: 10.2337/dc17-0237 contributor: fullname: Rajasekeran – volume: 4 year: 2020 ident: B17 article-title: Early initiation of sodium-glucose linked transporter inhibitors (SGLT-2i) and associated metabolic and electrolyte outcomes in diabetic kidney transplant recipients publication-title: Endocrinol Diabetes Metab doi: 10.1002/edm2.185 contributor: fullname: Song – volume: 22 year: 2022 ident: B26 article-title: Intermediate term outcomes of SGLT2 inhibitors amongst diabetic kidney transplant recipients publication-title: Am J Transplant contributor: fullname: Song – volume: 69 start-page: 78 year: 2017 ident: B22 article-title: Renin-angiotensin system blockade and long-term clinical outcomes in kidney transplant recipients: A meta-analysis of randomized controlled trials publication-title: Am J Kidney Dis doi: 10.1053/j.ajkd.2016.08.018 contributor: fullname: Hiremath – volume: 52 year: 2020 ident: B15 article-title: Outcomes of SGLT2 inhibitors use in diabetic renal transplant patients publication-title: Transplant Proc doi: 10.1016/j.transproceed.2019.11.007 contributor: fullname: Alkindi – volume: 51 year: 2019 ident: B12 article-title: Use of empagliflozin in recipients of kidney transplant: A report of 8 cases publication-title: Transplant Proc doi: 10.1016/j.transproceed.2019.05.023 contributor: fullname: Attallah – volume: 7 year: 2019 ident: B6 article-title: SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: A systematic review and meta-analysis publication-title: Lancet Diabetes Endocrinol doi: 10.1016/S2213-8587(19)30256-6 contributor: fullname: Neuen – volume: 106 year: 2022 ident: B20 article-title: SGLT2i after kidney transplantation: Ready for prime time publication-title: Transplantation doi: 10.1097/TP.0000000000004227 contributor: fullname: Francis – volume: 20 start-page: 107 year: 2021 ident: B24 article-title: SGLT2 inhibitors and lower limb complications: The diuretic-induced hypovolemia hypothesis publication-title: Cardiovasc Diabetol doi: 10.1186/s12933-021-01301-x contributor: fullname: Potier – volume: 29 year: 2019 ident: B11 article-title: Efficacy and safety of canagliflozin in kidney transplant patients publication-title: Indian J Nephrol doi: 10.4103/ijn.IJN_2_18 contributor: fullname: Shah – volume: 75 year: 2020 ident: B3 article-title: Mechanisms of cardiorenal effects of sodium-glucose cotransporter 2 inhibitors: JACC state-of-the-Art review publication-title: J Am Coll Cardiol doi: 10.1016/j.jacc.2019.11.031 contributor: fullname: Zelniker – volume: 19 year: 2019 ident: B10 article-title: Empagliflozin in posttransplantation diabetes mellitus: A prospective, interventional pilot study on glucose metabolism, fluid volume, and patient safety publication-title: Am J Transplant doi: 10.1111/ajt.15223 contributor: fullname: Schwaiger – volume: 22 year: 2022 ident: B27 article-title: Sodium-glucose Co-transporter 2 inhibitors; short-term outcome in diabetic kidney transplant recipients publication-title: Am J Transplant contributor: fullname: Yagan – volume: 393 year: 2019 ident: B2 article-title: SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcome trials publication-title: Lancet doi: 10.1016/S0140-6736(18)32590-X contributor: fullname: Zelniker – volume: 42 year: 2019 ident: B8 article-title: Efficacy and safety of empagliflozin in renal transplant recipients with posttransplant diabetes mellitus publication-title: Diabetes Care doi: 10.2337/dc19-0093 contributor: fullname: Halden – volume: 385 year: 2021 ident: B4 article-title: Empagliflozin in heart failure with a preserved ejection fraction publication-title: N Engl J Med doi: 10.1056/NEJMoa2107038 contributor: fullname: Anker – volume: 77 start-page: 23 year: 2021 ident: B5 article-title: Relative and absolute risk reductions in cardiovascular and kidney outcomes with canagliflozin across KDIGO risk categories: Findings from the CANVAS program publication-title: Am J Kidney Dis doi: 10.1053/j.ajkd.2020.06.018 contributor: fullname: Neuen – volume: 17 year: 2017 ident: B23 article-title: Effect of empagliflozin on tacrolimus-induced pancreas islet dysfunction and renal injury publication-title: Am J Transplant doi: 10.1111/ajt.14316 contributor: fullname: Jin – volume: 8 year: 2020 ident: B16 article-title: Efficacy and safety of SGLT-2 inhibitors for treatment of diabetes mellitus among kidney transplant patients: A systematic review and meta-analysis publication-title: Med Sci (Basel) doi: 10.3390/medsci8040047 contributor: fullname: Chewcharat – volume: 62 year: 2019 ident: B29 article-title: Canagliflozin reduces inflammation and fibrosis biomarkers: A potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease publication-title: Diabetologia doi: 10.1007/s00125-019-4859-4 contributor: fullname: Heerspink – volume: 51 year: 2020 ident: B28 article-title: Competing effects of renin angiotensin system blockade and sodium-glucose cotransporter-2 inhibitors on erythropoietin secretion in diabetes publication-title: Am J Nephrol doi: 10.1159/000507272 contributor: fullname: Marathias – volume: 36 year: 2022 ident: B18 article-title: Sodium-glucose cotransporter 2 inhibitors for treatment of diabetes mellitus after kidney transplantation publication-title: Clin Transplant doi: 10.1111/ctr.14718 contributor: fullname: Lemke – volume: 134 year: 2016 ident: B1 article-title: Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.116.021887 contributor: fullname: Heerspink – volume: 44 year: 2019 ident: B13 article-title: Sodium-glucose cotransporter 2 (SGLT2) inhibition in kidney transplant recipients with diabetes mellitus publication-title: Kidney Blood Press Res doi: 10.1159/000501854 contributor: fullname: Mahling – volume: 34 start-page: SP770 year: 2019 ident: B14 article-title: Sodium/glucose cotransporter 2 inhibitor for the treatment of diabetes in kidney transplant patients publication-title: Nephrol Dial Transplant doi: 10.1093/ndt/gfz103.SP770 contributor: fullname: Kong |
| SSID | ssj0002874079 |
| Score | 2.252326 |
| SecondaryResourceType | review_article |
| Snippet | Sodium-glucose cotransporter 2 inhibitor (SGLT2i), a glucosuric agent initially approved for use as an antidiabetic agent, was unexpectedly found to confer... |
| SourceID | pubmedcentral proquest crossref pubmed |
| SourceType | Open Access Repository Aggregation Database Index Database |
| StartPage | 1014241 |
| SubjectTerms | Nephrology |
| Title | Optimal use of SGLT2 inhibitors in diabetic kidney transplant recipients |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/37674999 https://www.proquest.com/docview/2862199805 https://pubmed.ncbi.nlm.nih.gov/PMC10479656 |
| Volume | 2 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3JTsMwELVoT1wQiK1sMhI3FNLYTpocERR6YJMAiVvkeBGB1o1Ie-DvmXEaROHGLcqm-GUSzxvPvCHkJIutSJm0gYmUCYTiSSCtKQKwD6WZZZoXGBoYPQ7uXtLLIcrkJG0tjE_aV0V55saTM1e--tzKaqLCNk8sfLi9QHmBDByRsEM64Bz-4OhvPlw0AJaSNRUywMCy0DpT4cIDY0hWBRPR8iz0x7X8nSH5Y8q5WidrC1-RnjfPtEFWjNsko3v4yCewe14bOrX08frmidHSvZZFiZ1zYJM2AdVS0fdSO_NJZ17BfAwgUhSzqLAGst4iz1fDp4tRsGiHECgm0ijQ2prYximXHAAGxyKzibWmb1isOUxFJpEWO0oJLVIFtE8KICc88ppxGWOGb5OumzqzS2gEPzXOC8XAIRGJ5GmhlUx5IWS_LzM26JHTFp68alQvcmALCGbuwcwRzHwBZo8ctwjmYJy44iCdmc7rnAFfwiK-ftwjOw2i3_dDGRmkWz2SLmH9fQIKXy8fAXvwAtjt-9_7_6X7ZBWHEPiEvgPSnX3MzSHp1Hp-5Gn5kbepL1NP02I |
| link.rule.ids | 230,315,729,782,786,866,887,27933,27934,53800,53802 |
| linkProvider | National Library of Medicine |
| linkToHtml | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT9wwEB7xOMCFgkrpQgFX6g2FTWwnmxwrXlt1oUhspd4ixw9tCutdseyBf98ZZ4PYcuMWxUmU-JvY89kz3wB8K1Inc65cZBNtI6lFFilnqwjtQxvuuBEVLQ3073o3f_LzC5LJydpcmBC0r6v61D-MT309CrGV07HutnFi3dvrM5IXKNAR6a7COv6wcfyKpf8NC0Y95ClFkyODHKzoOm-ntPXAOdFVyWWyPA-9cS7_j5F8Nelcfnjv627D1sLNZN-b9h1Ysf4j9H_h-DDG0_OZZRPH7q4GQ85qP6qrmoru4CFr1mJrze5r4-0zewri5w_Y_4x0MKaUPjnbhd-XF8OzfrSopBBpLvMkMsbZ1KW5UAKxQZ-kcJlzNrY8NQJnMZspR8WopJG5RsaoJPIakQS5uYJzKz7Bmp94-xlYguOhEJXm6MvITIm8MlrlopIqjlXBex04afu1nDaCGSUSDUKhDCiUhEK5QKEDX9uuL9GuabNCeTuZz0qOVIvy_-K0A3sNFC_PIwUaYmodyJdAermANLOXWxCboJ3dYrH__luPYaM_vB6Ugx83Pw9gkz4nCnGBX2Dt6XFuD2F1ZuZHwST_Ab8u6Cw |
| linkToPdf | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3fb9MwED6xIU28wBA_VmDgSXtDWRLbaRPepq2laGOr1E7iLXL8Q8tY3YiuD_z33DnNtI43eIsSJ0r8Xez7znefAQ6LzMmcKxfZVNtIatGPlLNVhPahDXfciIpCA-Pp4OJHfjokmZwvXS1MSNrXVX3kb-dHvr4OuZXNXMddnlg8-X5C8gIFOiJxY1y8BU_xp034A6Z-E4JGA-QqRVsngzysiJ23DS0_cE6UVXKZbs5FfzmYj_MkH0w8oxf_88q78HztbrLjts1LeGL9Kxhf4jgxx9OrpWULx6Zfz2ec1f66rmrafAcPWRuTrTX7WRtvf7O7IIJ-izgw0sNoqIxy-RquRsPZyTha76gQaS7zNDLG2cxluVACMULfpHB952xieWYEzma2rxxtSiWNzDUyRyWR34g0yM4VnFvxBrb9wts9YCmOi0JUmqNPI_tK5JXRKheVVEmiCj7oweeub8umFc4okXAQEmVAoiQkyjUSPTjour9E-6ZFC-XtYrUsOVIuqgNMsh68beG4fx4p0RBj60G-AdR9A9LO3ryC-AQN7Q6Pd_9-6yfYmZyOyvNvF2fv4Rl9TRTSAz_A9t2vld2HraVZfQxW-QcdReqs |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Optimal+use+of+SGLT2+inhibitors+in+diabetic+kidney+transplant+recipients&rft.jtitle=Frontiers+in+Nephrology+%28Online%29&rft.au=Pham%2C+Phuong-Thu+T&rft.au=Pham%2C+Phuong-Chi+T&rft.date=2022-11-10&rft.issn=2813-0626&rft.eissn=2813-0626&rft.volume=2&rft.spage=1014241&rft_id=info:doi/10.3389%2Ffneph.2022.1014241&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2813-0626&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2813-0626&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2813-0626&client=summon |